Clinical Trials and Projects

The following clinical trials and projects are available:

Clinical Trials:

Intranasal Ketamine for Suicidal ideation Comorbid with Alcohol Abuse

This project aims to evaluate the potential rapid and sustained antisuicidal and antidepressant effects of a single intranasal dose of ketamine in inpatients during a mood episode in Major Depressive Disorder (MDD) or Bipolar Disorder (BD) with or without comorbid recent abuse of alcohol.

Contact: Ana Ruiz

Projects:

Esketamine for Treatment Resistant Depression, Phase 4, Janssen

The purpose of this study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 milligram (mg) and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with treatment resistant depression (TRD), as assessed by the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from Day 1 (prerandomization) to the end of the 4 week double-blind treatment phase (Day 28).

Contact: Courtney Vecera, 713-741-6043

Evaluation of Biochemical and Epigenetic Biosignatures of Tears Exosomes in Depression and Sadness

The purpose of this study is to collect data on possible biomarkers of depression in human tears in order to better our understanding of the disease and potential treatments.

Contact: Courtney Vecera, 713-741-6043

Epigenetic Biomarkers of Suicidal Ideation

To investigate longitudinal changes in epigenetic markers (i.e., genome-wide DNA methylation levels) in patients during an acute suicidal episode and after its resolution.

Contact:  Courtney Vecera, 713-741-6043